|2.||Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
|1.||Burns, Jane C: 42 articles (12/2015 - 02/2003)|
|2.||Shulman, Stanford T: 24 articles (08/2015 - 02/2002)|
|3.||Kuo, Ho-Chang: 23 articles (03/2015 - 06/2007)|
|4.||Newburger, Jane W: 21 articles (03/2013 - 06/2003)|
|5.||Yang, Kuender D: 20 articles (03/2015 - 10/2002)|
|6.||Tremoulet, Adriana H: 18 articles (12/2015 - 07/2008)|
|7.||Rowley, Anne H: 18 articles (08/2015 - 02/2002)|
|8.||Miura, Masaru: 16 articles (07/2015 - 01/2004)|
|9.||Terai, Masaru: 16 articles (01/2015 - 02/2002)|
|10.||Saji, Tsutomu: 16 articles (09/2014 - 12/2004)|
|1.||Intravenous Immunoglobulins (IVIG)FDA Link
05/01/2002 - "Although the exact mode of action is still poorly understood, the efficacy of IVIg in several diseases, such as thrombocytopenic pupura and Kawasaki disease, has been proven in clinical trials. "
08/01/2003 - "The efficacy of a high dose (2 g/kg) of Thai Red-Cross IVIG in Kawasaki disease is excellent. "
10/01/1989 - "High-dose intravenous immune globulin treatment is effective in preventing the occurrence of coronary artery abnormalities in Kawasaki disease. "
01/01/2013 - "Studies that compare the efficacy of IVIG plus corticosteroid with that of IVIG in treating Kawasaki disease were included. "
12/01/2014 - "High-density genotyping of immune loci in Kawasaki disease and IVIG treatment response in European-American case-parent trio study."
02/01/2008 - "High-dose intravenous immunoglobulin (VIG) treatment for the acute stage of Kawasaki disease (KD) has shown to be effective and safe. "
08/01/2015 - "Glucocorticosteroids are more effective in controlling body temperature compared with intravenous immunoglobulin re-treatment in intravenous immunoglobulin-resistant Kawasaki disease children; however, glucocorticosteroids and intravenous immunoglobulin re-treatment showed no difference in the prevention of coronary artery lesions."
07/01/2010 - "In spite of the efficacy of intravenous immunoglobulin (IGIV), the absence of a specific diagnostic test and due to there being IGIV-refractory patients, Kawasaki disease is a major cause of coronary artery abnormalities (CAA). "
06/01/2009 - "More than half of the patients with acute Kawasaki disease, nonetheless, can be cured by giving only 1 gram per kilogram of immunoglobulin, thus reducing this aspect of the cost of treatment by half. "
11/01/1994 - "The mechanism of efficacy of intravenous immunoglobulin in Kawasaki disease."
04/01/2003 - "Following the standard treatment with intravenous gamma globulin, the initial symptoms and signs of Kawasaki disease resolved completely. "
03/01/1995 - "However, high-dose intravenous gamma-globulin (IVGG) is a safe and effective treatment for Kawasaki disease. "
08/07/1986 - "We conclude that high-dose intravenous gamma globulin is safe and effective in reducing the prevalence of coronary-artery abnormalities when administered early in the course of Kawasaki syndrome."
08/01/2000 - "We evaluated the efficacy of intravenous gamma-globulin (IVGG) administration for children with Kawasaki disease to establish whether additional, more advanced therapy is needed in intractable cases. "
06/06/1991 - "In children with acute Kawasaki disease, a single large dose of intravenous gamma globulin is more effective than the conventional regimen of four smaller daily doses and is equally safe."
|4.||Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
11/01/1990 - "The effects of intravenous gammaglobulin (IVGG) on changes in the peripheral blood mononuclear cell subsets during acute Kawasaki disease (KD) were studied by a random selection trial of IVGG plus Aspirin (group G) compared to Aspirin alone (group A). "
02/01/1988 - "Studies on the effect of long-term use of low dose aspirin in Kawasaki disease."
05/01/1987 - "To evaluate the effectiveness of gammaglobulin in decreasing the incidence of coronary artery lesions in Kawasaki disease, a randomized controlled study in 136 patients was conducted using high doses of gammaglobulin 400 mg/kg/d for 3 days plus aspirin 30 mg/kg/d (gammaglobulin group) and aspirin alone at the same dosage (aspirin group). "
02/01/1987 - "The effect of intravenous gammaglobulin (IVGG) on the immunoregulatory abnormalities found during acute Kawasaki syndrome (KS) was studied in a randomized trial of IVGG plus aspirin (ASA) versus ASA alone. "
11/10/1984 - "The ability of high-dose intravenous gammaglobulin (IVGG) to prevent the coronary artery lesion of Kawasaki disease has been studied in a multicentre controlled trial of IVGG plus aspirin versus aspirin alone, aspirin being the conventional treatment for Kawasaki disease. "
|5.||Prednisolone (Predate)FDA LinkGeneric
11/01/2012 - "Adding prednisolone to standard immunoglobulin therapy is beneficial for patients with severe Kawasaki disease."
09/01/2014 - "The present paper reviews the roles of prednisolone therapy for acute phase Kawasaki disease patients."
09/01/2014 - "Prednisolone therapy for acute phase Kawasaki disease had been considered to be controversial for several decades. "
09/01/2014 - "[Prednisolone therapy for Kawasaki disease]."
04/28/2012 - "Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial."
|6.||Antineutrophil Cytoplasmic Antibodies (ANCA)IBA
01/01/2012 - "To study the value of anti-neutrophil cytoplasmic antibody (ANCA) in diagnosis of Kawasaki disease (KD). "
01/01/2012 - "Serum ANCA was detected in 30 children with typical Kawasaki disease (TKD) and in 16 with incomplete Kawasaki disease (IKD) in the acute and the recovery phases respectively. "
01/01/2012 - "[Value of anti-neutrophil cytoplasmic antibody in diagnosis of Kawasaki disease]."
05/01/1993 - "Newer investigative procedures and therapeutic approaches have led to more accurate diagnoses and improved outcome but further advances await a better understanding of the vasculitides: polyarteritis; Kawasaki disease; Wagener's granulomatosis; and ANCA in childhood."
01/01/2007 - "We screened the sera of 148 MPO-ANCA positive patients from six vasculitic syndromes: rapidly progressive gromerulonephritis (RPGN), microscopic polyangiitis (MPA), idiopathic crescentic glomerulonephritis (I-CrGN), classic polyangiitis nodosa (cPAN), Churg-Strauss syndrome (CSS), Kawasaki disease (KD); and from patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). "
05/01/2010 - "Urinary cytokines and renal Doppler study in Kawasaki disease."
03/01/1995 - "This study provides evidence to support the involvement of activated mononuclear cells, both T cells and monocytes and their secreted soluble products, cytokines, in the pathogenesis of Kawasaki disease."
11/01/2015 - "In all patients, the plasma level of Th1 cytokines (IFN-γ, IL-2) and Th2 cytokines (IL-4 and IL-10) were markedly elevated during the acute stage of Kawasaki disease. "
11/01/2014 - "Downregulation of Th17 cells and the related cytokines with treatment in Kawasaki disease."
09/01/2014 - "[Cytokines in Kawasaki disease]."
|8.||Adrenal Cortex Hormones (Corticosteroids)IBA
07/01/2009 - "We included randomised trials comparing the addition of corticosteroids to conventional primary therapy for Kawasaki disease. "
09/01/2006 - "A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome."
06/01/2003 - "Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial."
10/01/1999 - "Corticosteroids are considered to be contraindicated during the acute phase of Kawasaki disease (KD) based on unfavorable results in early studies. "
11/08/2015 - "Three options of using corticosteroids for the treatment of patients during the acute phase of Kawasaki disease, have been considered. "
|9.||infliximab (Remicade)FDA Link
11/01/2010 - "Infliximab administration effective in the treatment of refractory Kawasaki disease."
07/01/2006 - "Efficacy of infliximab in long-lasting refractory Kawasaki disease."
05/17/2014 - "Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial."
05/17/2014 - "The addition of infliximab to primary treatment in acute Kawasaki disease did not reduce treatment resistance. "
01/01/2014 - "Infliximab as rescue therapy in refractory Kawasaki disease."
|10.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/01/2010 - "There have been genetic studies assessing the association between tumor necrosis factor (TNF)-α-308 and Kawasaki disease (KD) but the results have been conflicting due to lack of power. "
05/15/2006 - "In this study, we report rapid production of TNF-alpha in the peripheral immune system after disease induction in a murine model of Kawasaki disease. "
01/01/2015 - "[Recent advance in tumor necrosis factor-α blockade treatment for Kawasaki disease]."
08/01/2010 - "A systematic review and meta-analysis of tumor necrosis factor α-308 polymorphism and Kawasaki disease."
09/01/2008 - "Our findings suggest that CRP +1444 C-->T and TNF-alpha -308 G-->A polymorphisms are associated with predisposition to Kawasaki disease and, in patients with Kawasaki disease, increased carotid arterial stiffness and intima-media thickness in the long-term."
02/01/2012 - "The aim of the present study was to investigate the long-term efficacy of plasma exchange (PE) treatment for refractory Kawasaki disease. "
06/01/2012 - "Efficacy of plasma exchange therapy for Kawasaki disease by cytokine profiling."
02/01/2012 - "Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease."
08/01/2015 - "Search terms used included "Kawasaki disease" and "plasma exchange" to extract articles that described KD cases treated with PE. "
04/01/2008 - "A report of two cases of Kawasaki disease treated with plasma exchange."
04/01/1990 - "Thus an internal mammary artery graft has proved to be satisfactory in the management of children with coronary artery obstruction caused by Kawasaki disease; it appears that both the quality of life and the life expectancy of those patients can be improved by the surgery."
07/01/2014 - "We tested the hypothesis that OCT could identify coronary abnormalities not seen by angiography in children with a history of Kawasaki disease (KD) and pediatric heart transplant (TX) recipients. "
10/01/2013 - "Decreased portal vein flow during Kawasaki disease in a liver transplant patient."
06/01/2012 - "Histopathology of the longest-lived saphenous vein graft in a patient with Kawasaki disease."
11/01/2006 - "Redo off-pump coronary bypass grafting with arterial grafts for Kawasaki disease."
|3.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
07/01/2010 - "To compare the long-term efficacy of percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) for stenotic lesions after Kawasaki disease. "
10/01/2001 - "The purpose of this study was to assess the long-term clinical outcome of coronary artery bypass grafting in pediatric patients with Kawasaki disease. "
09/01/2014 - "[Coronary artery bypass grafting for cardiovascular sequelae in Kawasaki disease]."
06/01/2012 - "[Coronary artery bypass after Kawasaki disease]."
09/01/2010 - "Pediatric coronary artery bypass is performed for ischemic complications of Kawasaki disease, congenital coronary anomalies, and iatrogenic pediatric coronary artery problems. "
|4.||Transplantation (Transplant Recipients)
07/01/2014 - "Feasibility of optical coherence tomography in children with Kawasaki disease and pediatric heart transplant recipients."
02/01/2013 - "In the absence of any symptoms consistent with Kawasaki disease in the transplant recipient, this appears to be a case of Kawasaki disease in the organ donor manifesting with coronary anomalies in the transplant recipient. "
07/01/2000 - "Experience is reported in children with prior Kawasaki disease or heart transplant recipients, as well as patients with congenital coronary abnormalities. "
10/01/1997 - "In these 10 patients, the timing of transplantation was within 6 months after diagnosis of Kawasaki disease (4 patients), 1 to 5 years after diagnosis (3 patients), and 9 to 12 years after diagnosis (3 patients). "
02/01/2013 - "An apparent case of undiagnosed donor Kawasaki disease manifesting as coronary artery aneurysm in a pediatric heart transplant recipient."
06/25/2002 - "Catheter intervention for Kawasaki disease can be accomplished and can be effective in the short term, but the long-term efficacy should be verified by further study."
06/25/2002 - "The purpose of this study was to assess the sequential follow-up results of catheter intervention in Kawasaki disease by use of quantitative coronary angiography (QCA) and intravascular ultrasound imaging. "
06/25/2002 - "Sequential follow-up results of catheter intervention for coronary artery lesions after Kawasaki disease: quantitative coronary artery angiography and intravascular ultrasound imaging study."
10/01/2001 - "The Research Committee of Ministry of Health, Labour and Welfare 'Study of treatment and long-term management in Kawasaki disease' reported the guidelines for catheter intervention in coronary artery lesion in Kawasaki disease in this paper. "
02/01/2011 - "Rotational ablation may be the most appropriate catheter intervention technique for patients with Kawasaki disease. "